"Chemotherapy, Adjuvant" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drug therapy given to augment or stimulate some other form of treatment such as surgery or radiation therapy. Adjuvant chemotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.
Descriptor ID |
D017024
|
MeSH Number(s) |
E02.186.170 E02.319.170
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Chemotherapy, Adjuvant".
Below are MeSH descriptors whose meaning is more specific than "Chemotherapy, Adjuvant".
This graph shows the total number of publications written about "Chemotherapy, Adjuvant" by people in this website by year, and whether "Chemotherapy, Adjuvant" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1998 | 0 | 1 | 1 |
2004 | 0 | 1 | 1 |
2005 | 0 | 1 | 1 |
2006 | 0 | 1 | 1 |
2007 | 0 | 1 | 1 |
2009 | 0 | 2 | 2 |
2010 | 1 | 3 | 4 |
2011 | 0 | 3 | 3 |
2012 | 1 | 10 | 11 |
2013 | 0 | 1 | 1 |
2014 | 0 | 4 | 4 |
2015 | 0 | 3 | 3 |
2016 | 3 | 3 | 6 |
2017 | 0 | 3 | 3 |
2018 | 0 | 1 | 1 |
2020 | 0 | 1 | 1 |
2021 | 1 | 0 | 1 |
2022 | 0 | 1 | 1 |
2023 | 0 | 1 | 1 |
2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Chemotherapy, Adjuvant" by people in Profiles.
-
Trends in chemotherapy use for early-stage breast cancer from 2006 to 2019. Breast Cancer Res. 2024 Jun 13; 26(1):101.
-
Underutilization or appropriate care? Assessing adjuvant chemotherapy use and survival in 3 heterogenous subpopulations with stage II/III colorectal cancer within a large integrated health system. J Manag Care Spec Pharm. 2023 Jun; 29(6):635-646.
-
The benefits and harms of adjuvant chemotherapy for non-small cell lung cancer in patients with major comorbidities: A simulation study. PLoS One. 2022; 17(11):e0263911.
-
Breast MRI during Neoadjuvant Chemotherapy: Lack of Background Parenchymal Enhancement Suppression and Inferior Treatment Response. Radiology. 2021 11; 301(2):295-308.
-
Implementation of a Multidisciplinary Expert Testicular Cancer Tumor Board Across a Large Integrated Healthcare Delivery System Via Early Case Ascertainment. JCO Clin Cancer Inform. 2021 02; 5:187-193.
-
Association of Diabetes and Other Clinical and Sociodemographic Factors With Guideline-concordant Breast Cancer Treatment for Breast Cancer. Am J Clin Oncol. 2020 02; 43(2):101-106.
-
Adjuvant endocrine therapy for breast cancer patients: impact of a health system outreach program to improve adherence. Breast Cancer Res Treat. 2020 Feb; 180(1):219-226.
-
Personal and clinical social support and adherence to adjuvant endocrine therapy among hormone receptor-positive breast cancer patients in an integrated health care system. Breast Cancer Res Treat. 2018 Aug; 170(3):623-631.
-
Changes in bone mineral density in women with breast cancer receiving aromatase inhibitor therapy. Breast Cancer Res Treat. 2018 Apr; 168(2):523-530.
-
Muscle mass at the time of diagnosis of nonmetastatic colon cancer and early discontinuation of chemotherapy, delays, and dose reductions on adjuvant FOLFOX: The C-SCANS study. Cancer. 2017 Dec 15; 123(24):4868-4877.